1Goldhirsch A, Wood WC, Gclber RD,et al. Meeting highlights: updated in ternational expert consensus on the primary therapy of early breast cancer[J].J Clin Oncol,2003,21 (16) :3357 -3365.
2National Institutes of Health Consensus Development Conference [ J ]. J Natl Cancer Inst Monogr, 2001,30:151 -152.
3Carlson RW, Edge SB, Theriauh RL.NCCN : Breast cancer[ J]. Cancer Control, 2001,8(6) :54 -61.
4Bonadonna G, Moliterni A, ZambettiM, et al. 30 years'follow up of randomized studies of adjuvant CMF in operable breast cancer: cohort study[J].BMJ, 2005,330(7485) :217.
5Fisher B, Brown AM, Dimotrov NV, et al. Two months of doxorubicin-cyclophosphamid with and without interval reinduction therapy compared with sixmonths of cyclophosphamid, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: results from NSABP B-15[J]. J Clin Oncol, 1990,8(9) :1483 - 1496.
6Fisher B, Jeong JH, Anderson S, et al.Treatment of axillary lymph node-negative, estrogen receptor negative breastcancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials [J]. J Nail Cancer Inst 2004:96(24) : 1823 -1831.
7Hutchins L, Green S, Ravdin P, et al.CMF versus CAF with and without tamoxifen in high risk node negative breast cancer patient and a natural history follow-up study in low risk node negative patients:first results of intergroup trial in 0102 [J]. Proc Am Soc Clin Oncol, 1998,17 :la ( Abst 2).
8Henderson IC, Berry D, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from eslatingdoxorubicin dose in an adjuvant chemotherapy regimen for patient with nodepositive primary breast cancer [J]. J Clin Oncol,2003,21 (6) :976 -983.
9Martin M, Pienkowski T, Mackey J.TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients,BCIRG001 : 55 months follow-up [ J ].Breast Cancer Res Treat, 2003, 82( supplement 1 ) : abst 43.
